PMID- 10665910
OWN - NLM
STAT- MEDLINE
DCOM- 20000217
LR  - 20190722
IS  - 0046-8177 (Print)
IS  - 0046-8177 (Linking)
VI  - 31
IP  - 1
DP  - 2000 Jan
TI  - HER-2/neu gene amplification by FISH predicts poor survival in Barrett's 
      esophagus-associated adenocarcinoma.
PG  - 35-9
AB  - The HER-2/neu oncogene is localized to chromosome 17q and shares significant 
      homology with the epidermal growth factor receptor. HER-2/neu protein 
      overexpression has been associated with poor prognosis in a variety of tumors, 
      but its significance in Barrett's esophagus-associated adenocarcinoma (BEAd) is 
      unknown. Therefore, the aim of this study was to evaluate the prevalence and 
      prognostic value of HER-2/neu gene amplification by fluorescence in situ 
      hybridization (FISH) in 63 cases of BEAd. Routinely processed tissue sections 
      from resection specimens of 63 patients with BEAd (M/F ratio, 10:1; mean age, 63 
      years) were assayed for HER-2/neu gene amplification by FISH using the Ventana 
      unique sequence probe (Ventana Medical Systems, Inc, Tuscon, AZ). FISH results 
      were correlated with the pathological features of the tumors and with patient 
      survival. Clinical follow-up data were available for 54 patients (mean follow-up, 
      31 months [range, 1 to 152 months]). The HER-2/ neu gene was amplified in 12 of 
      63 (19%) cases. The presence of HER-2/neu gene amplification showed a trend 
      toward a correlation with depth of tumor invasion (P = .07), lymph node 
      metastasis (P = .13), and pathological stage (P = .14), but did not correlate 
      with any of the other pathological features, such as degree of differentiation or 
      tumor size. On both univariate and multivariate analysis, HER-2/neu gene 
      amplification was associated with shortened survival (P = .03). HER-2/neu 
      oncogene amplification, as determined by FISH, correlates with shortened patient 
      survival and independently predicts poor outcome in patients with BEAd.
FAU - Brien, T P
AU  - Brien TP
AD  - Department of Pathology & Laboratory Medicine, Albany Medical College, NY 12208, 
      USA.
FAU - Odze, R D
AU  - Odze RD
FAU - Sheehan, C E
AU  - Sheehan CE
FAU - McKenna, B J
AU  - McKenna BJ
FAU - Ross, J S
AU  - Ross JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
EIN - Hum Pathol 2000 Apr;31(4):524
MH  - Adenocarcinoma/etiology/*genetics/pathology/physiopathology
MH  - Adult
MH  - Aged
MH  - Barrett Esophagus/*complications
MH  - Esophageal Neoplasms/etiology/*genetics/pathology/physiopathology
MH  - Female
MH  - Forecasting
MH  - *Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Receptor, ErbB-2/*genetics
MH  - Survival Analysis
EDAT- 2000/02/09 09:00
MHDA- 2000/02/19 09:00
CRDT- 2000/02/09 09:00
PHST- 2000/02/09 09:00 [pubmed]
PHST- 2000/02/19 09:00 [medline]
PHST- 2000/02/09 09:00 [entrez]
AID - S0046-8177(00)80195-1 [pii]
AID - 10.1016/s0046-8177(00)80195-1 [doi]
PST - ppublish
SO  - Hum Pathol. 2000 Jan;31(1):35-9. doi: 10.1016/s0046-8177(00)80195-1.